Thyroid Cancer Therapeutics - Pipeline Assessment and Market Forecast to 2017

Thyroid Cancer Therapeutics - Pipeline Assessment and Market Forecast to 2017

Summary

GlobalData, the industry analysis specialist, has released its new report, “Thyroid Cancer Therapeutics - Pipeline Assessment and Market Forecast to 2017”. The report is an essential source of information and analysis on the global thyroid cancer therapeutics market. The report identifies the key trends shaping and driving the global thyroid cancer therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to sithyroid cancerificantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global thyroid cancer therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.
GlobalData estimated that the thyroid cancer market was worth $55m in 2010. The major reason for the limited market revenues was the lack of approved drugs for the treatment of thyroid cancer. Thyroid cancer is mainly treated by surgery and radiotherapy. Chemotherapy has fewer roles to play in the treatment. Mainly doxorubicin is used as an off-label drug for treating the patients with anaplastic thyroid cancer; also some other off-label drugs such as cisplatin and carboplatin are used, but they have lower response rates. The high growth forecast for the thyroid cancer therapeutics market is primarily attributed to a strong pipeline. The upcoming four pipeline molecules (Pre-registration (1) and Phase III (3)) in the next seven years will take a steep rise in the market. Overall, between 2010 and 2017, the thyroid cancer market is expected to grow at a CAGR (Compound Annual Growth Rate) of 27.34% to reach $298m by 2017.

Scope

The report provides information on the key drivers and challenges of the thyroid cancer therapeutics market. Its scope includes -

• Annualized seven key markets (US, France, Germany, Italy, Spain, UK and Japan) thyroid cancer therapeutics market revenues data from 2005 to 2010, forecast for seven years to 2017.
• Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends by seven key markets. Pipeline candidates fall under major therapeutic classes such as Tyrosine Kinase Inhibitor, VEGFR Inhibitors, Multi kinase inhibitors, vascular disrupting agents, Topoisomerase inhibitor, Potent deacetylase inhibitor, Serine/threonine-protein kinase, liposomal FAK, Antifolate, SYK Inhibitor, mTOR Inhibitor, Peroxisome proliferator-activated receptor gamma agonist, Multi kinase angiostenin inhibitor, BRAF Kinase inhibitor.
• Analysis of the current and future competition in the seven key countries thyroid cancer therapeutics market. Key market players covered Bayer, Oynx Pharmaceutical, AstraZeneca PLC, Oxigene Inc, Exelixis Inc., Novartis AG, Pfizer, Eisai Co., Daichii SankyoLtd.
• Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
• Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the thyroid cancer therapeutics market.
• Analysis of key recent licensing and partnership agreements in thyroid cancer therapeutics market

Reasons to buy
The report will enhance your decision making capability. It will allow you to -

• Develop and desithyroid cancer your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.
• Develop business strategies by understanding the trends shaping and driving the global thyroid cancer therapeutics market.
• Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global thyroid cancer therapeutics market in future.
• Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
• Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
• Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
• What’s the next big thing in the global thyroid cancer therapeutics market landscape? - Identify, understand and capitalize.

Contents

1 TABLE OF CONTENTS

1.1 List of Tables
1.2 List of Figures

2 THYROID CANCER THERAPEUTICS : INTRODUCTION

2.1 Disease Overview
  2.1.1 Thyroid cancer
2.2 Epidemiology
2.3 Etiology
2.4 Symptoms
2.5 Diagnosis
2.6 Prognosis
2.7 Staging and Treatment of Thyroid Cancer
2.8 Treatment Options
2.9 GlobalData Pipeline Report Guidance

3 THYROID CANCER THERAPEUTICS: MARKET CHARACTERIZATION

3.1 Overview
3.2 Thyroid Cancer Therapeutics Market Size (2005-2010) – Global
3.3 Thyroid Cancer Therapeutics Market Forecast (2010-2017) – Global
3.4 Thyroid Cancer Therapeutics Market Size (2005-2010) – The US
3.5 Thyroid Cancer Therapeutics Market Forecast (2010-2017) – The US
3.6 Thyroid Cancer Therapeutics Market Size (2005-2010) – France
3.7 Thyroid Cancer Therapeutics Market Forecast (2010-2017) – France
3.8 Thyroid Cancer Therapeutics Market Size (2005-2010) – Germany
3.9 Thyroid Cancer Therapeutics Market Forecast (2010-2017) – Germany
3.10 Thyroid Cancer Therapeutics Market Size (2005-2010) – Italy
3.11 Thyroid Cancer Therapeutics Market Forecast (2010-2017) – Italy
3.12 Thyroid Cancer Therapeutics Market Size (2005-2010) – Spain
3.13 Thyroid Cancer Therapeutics Market Forecast (2010-2017) – Spain
3.14 Thyroid Cancer Therapeutics Market Size (2005-2010) – the UK
3.15 Thyroid Cancer Therapeutics Market Forecast (2010-2017) – the UK
3.16 Thyroid Cancer Therapeutics Market Size (2005-2010) – Japan
3.17 Thyroid Cancer Therapeutics Market Forecast (2010-2017) – Japan
3.18 Drivers and Barriers for the Thyroid Cancer Therapeutics Market
  3.18.1 Drivers for the Thyroid Cancer Therapeutics Market
  3.18.2 Barriers for the Thyroid Cancer Therapeutics Market
3.19 Opportunity and Unmet Needs
3.20 Key Takeaway

4 THYROID CANCER THERAPEUTICS: COMPETITIVE ASSESSMENT

4.1 Overview
  4.1.1 Strategic Competitor Assessment
4.2 Product Profile for the Major Marketed Products in Thyroid Cancer
  4.2.1 Zactima (vandetanib, ZD6474)
  4.2.2 Doxorubicin
4.3 Key Takeaway

5 THYROID CANCER THERAPEUTICS: PIPELINE ASSESSMENT

5.1 Overview
5.2 Strategic Pipeline Assessment
5.3 Pipeline Analysis by Phase of Development
  5.3.1 Thyroid Cancer Therapeutics – Phase III Clinical Pipeline
  5.3.2 Thyroid Cancer Therapeutics – Phase II Clinical Pipeline
  5.3.3 Thyroid Cancer Therapeutics – Phase I Clinical Pipeline
  5.3.4 Thyroid Cancer Therapeutics – Preclinical Pipeline
  5.3.5 Thyroid Cancer Therapeutics – Discovery Pipeline
5.4 Technology Trends Analytic Framework
5.5 Thyroid Cancer Therapeutics Market: Clinical Pipeline by Mechanism of Action
5.6 Promising Drugs Under Clinical Development
  5.6.1 Nexavar (sorafenib)
  5.6.2 Zybrestat (combretastatin A4 phosphate)
  5.6.3 XL 184
5.7 Key Takeaway

6 THYROID CANCER THERAPEUTICS: CLINICAL TRIALS MAPPING

6.1 Clinical Trials by Country
6.2 Clinical Trials by Phase
6.3 Clinical Trials by Phase
6.4 Prominent Sponsors
6.5 Top Sponsors Participating in Thyroid Cancer Therapeutics Clinical Trials

7 THYROID CANCER THERAPEUTICS: STRATEGIC ASSESSMENT

7.1 Key Events Impacting the Future Market
7.2 Future Market Competition Scenario

8 THYROID CANCER THERAPEUTICS: FUTURE PLAYERS

8.1 Introduction
8.2 Company Profiles for the Promising Drugs
  8.2.1 Astra Zeneca
  8.2.2 Bayer
  8.2.3 Exelixis
  8.2.4 Oxigene
8.3 Other Companies in the Thyroid Cancer Therapeutics Market

9 THYROID CANCER THERAPEUTICS: LICENSING AND PARTNERSHIP DEALS

10 THYROID CANCER THERAPEUTICS: APPENDIX

10.1 Abbreviations
10.2 Methodology
  10.2.1 Coverage
  10.2.2 Secondary Research
  10.2.3 Forecasting
  10.2.4 Primary Research
  10.2.5 Expert Panel Validation
10.3 Contact Us
10.4 Disclaimer
10.5 Bibliography

LIST OF TABLES

Table 1: Staging of Thyroid Cancer
Table 2: TNM Classification: Papillary Thyroid Cancer
Table 3: TNM Classification: Medullary Thyroid Cancer
Table 4: TNM Classification: Anaplastic Thyroid Cancer
Table 5: Thyroid Cancer Therapeutics Market, Global, Revenue ($m), 2005-2010
Table 6: Thyroid Cancer Therapeutics Market, Global, Forecast ($m), 2010-2017
Table 7: Thyroid Cancer Therapeutics Market, the US, Revenue ($m), 2005-2010
Table 8: Thyroid Cancer Therapeutics Market, Global, Forecast ($m), 2010-2017
Table 9: Thyroid Cancer Therapeutics Market, the US, Revenue ($m), 2005-2010
Table 10: Thyroid Cancer Therapeutics Market, France, Forecast ($m), 2010-2017
Table 11: Thyroid Cancer Therapeutics Market, Germany, Revenue ($m), 2005-2010
Table 12: Thyroid Cancer Therapeutics Market, Germany, Forecast ($m), 2010-2017
Table 13: Thyroid Cancer Therapeutics Market, Italy, Revenue ($m), 2005-2010
Table 14: Thyroid Cancer Therapeutics Market, Italy, Forecast ($m), 2010-2017
Table 15: Thyroid Cancer Therapeutics Market, Spain, Revenue ($m), 2005-2010
Table 16: Thyroid Cancer Therapeutics Market, Spain, Forecast ($m), 2010-2017
Table 17: Thyroid Cancer Therapeutics Market, the UK, Revenue ($m), 2005-2010
Table 18: Thyroid Cancer Therapeutics Market, the UK, Forecast ($m), 2010-2017
Table 19: Thyroid Cancer Therapeutics Market, Japan, Revenue ($m), 2005-2010
Table 20: Thyroid Cancer Therapeutics Market, Japan, Forecast ($m), 2010-2017
Table 21: Thyroid Cancer Therapeutics – Phase III Clinical Pipeline, 2011
Table 22: Thyroid Cancer Therapeutics – Phase II Clinical Pipeline, 2011
Table 23: Thyroid Cancer Therapeutics – Phase I Clinical Pipeline, 2011
Table 24: Thyroid Cancer Therapeutics – Preclinical Pipeline, 2011
Table 25: Thyroid Cancer Therapeutics – Discovery Pipeline, 2011
Table 26: Thyroid Cancer Therapeutics Market – Clinical Trials by Country, 2011
Table 27: Thyroid Cancer Therapeutics Market – Clinical Trials by Phase, 2011
Table 28: Thyroid Cancer Therapeutics Market – Clinical Trials by Trial Status, 2011
Table 29: Thyroid Cancer Therapeutics Market – Clinical Trials by Overall Sponsors, 2011
Table 30: Thyroid Cancer Therapeutics Market – Clinical Trials by Prominent Sponsors, 2011
Table 31: Thyroid Cancer Therapeutics Market – Clinical Trials by Top Sponsors, 2011
Table 32: AstraZeneca PLC –Oncology ( Phase III) Pipeline Products, 2011
Table 33: AstraZeneca PLC – Deals
Table 34: Bayer Healthcare Pharma –Oncology (Phase III) Pipeline Products, 2011
Table 35: Bayer Healthcare Pharma – Thyroid Cancer Pipeline Product, 2011
Table 36: Bayer Healthcare Pharma – Deals
Table 37: Exelixis, Inc. – Oncology Pipeline Products, 2011
Table 38: Exelixis, Inc. – Thyroid Cancer Pipeline Product, 2011
Table 39: Oxigene Inc. – Deals
Table 40: Oxigene, Inc –Oncology Pipeline Products, 2011
Table 41: Oxigene, Inc. – Thyroid Cancer Pipeline Product, 2011
Table 42: Oxigene Inc. – Deals
Table 43: Thyroid Cancer Therapeutics – Other Companies in the Thyroid Cancer Therapeutics Market, 2010
Table 44: Thyroid Cancer Therapeutics, Global, Deals, 2010

LIST OF FIGURES

Figure 1: Classification of Papillary Thyroid Cancer
Figure 2: Classification of Follicular Thyroid Cancer
Figure 3: Incidence and Mortality for Thyroid Cancer in 2010 for Seven Major Markets
Figure 4: Thyroid Cancer Therapeutics Market, Global, Market Revenue ($m), 2005-2010
Figure 5: Thyroid Cancer Therapeutics Market, Global, Forecast ($m), 2010-2017
Figure 6: Thyroid Cancer Therapeutics Market, the US, Revenue ($m), 2005-2010
Figure 7: Thyroid Cancer Therapeutics Market, the US, Forecast ($m), 2010-2017
Figure 8: Thyroid Cancer Therapeutics Market, France, Revenue ($m), 2005-2010
Figure 9: Thyroid Cancer Therapeutics Market, France, Forecast ($m), 2010-2017
Figure 10: Thyroid Cancer Therapeutics Market, Germany, Revenue ($m), 2005-2010
Figure 11: Thyroid Cancer Therapeutics Market, Germany, Forecast ($m), 2010-2017
Figure 12: Thyroid Cancer Therapeutics Market, Italy, Revenue ($m), 2005-2010
Figure 13: Thyroid Cancer Therapeutics Market, Italy, Forecast ($m), 2010-2017
Figure 14: Thyroid Cancer Therapeutics Market, Spain, Revenue ($m), 2005-2010
Figure 15: Thyroid Cancer Therapeutics Market, Spain, Forecast ($m), 2010-2017
Figure 16: Thyroid Cancer Therapeutics Market, the UK, Revenue ($m), 2005-2010
Figure 17: Thyroid Cancer Therapeutics Market, the UK, Forecast ($m), 2010-2017
Figure 18: Thyroid Cancer Therapeutics Market, Japan, Revenue ($m), 2005-2010
Figure 19: Thyroid Cancer Therapeutics Market, Japan, Forecast ($m), 2010-2017
Figure 20: Opportunity and Unmet Need in the Thyroid Cancer Therapeutics Market, 2010
Figure 21: Thyroid Cancer Therapeutics Pipeline by Phase of Clinical Development, 2011
Figure 22: Technology Trends Analytic Framework for the Thyroid Cancer Therapeutics Pipeline, 2011
Figure 23: Technology Trends Analytic Framework for the Thyroid Cancer Therapeutics Pipeline – Description, 2011
Figure 24: Thyroid Cancer Therapeutics Market – Clinical Pipeline by Mechanism of Action, 2011
Figure 25: Thyroid Cancer Therapeutics Market – Clinical Trials by Country, 2011
Figure 26: Thyroid Cancer Therapeutics Market – Clinical Trials by Phase, 2011
Figure 27: Thyroid Cancer Therapeutics Market – Clinical Trials by Trial Status, 2011
Figure 28: Thyroid Cancer Therapeutics Market – Clinical Trials by Overall Sponsors, 2011
Figure 29: Thyroid Cancer Therapeutics Market – Clinical Trials by Prominent Sponsors, 2011
Figure 30: Thyroid Cancer Therapeutics Market – Clinical Trials by Top Sponsors, 2011
Figure 31: Thyroid Cancer Therapeutics Market – Drivers and Barriers, 2010
Figure 32: Thyroid Cancer Therapeutics Market – Implications for Future Market Competition, 2010
Figure 33: Thyroid Cancer Therapeutics Market – Future Players, 2011
Figure 34: GlobalData Market Forecasting Model

COMPANIES MENTIONED

Astra Zeneca
Bayer
Exelixis
Oxigene Skip to top